Florey Biosciences, Inc.

Florey Biosciences, Inc. is a biotechnology company focused on engineered probiotics, providing innovative solutions for gut health management, specifically targeting antibiotic-associated disturbances. Florey Biosciences develops engineered probiotics aimed at improving gut health. Founded in 2024 and based in Cambridge, US, the company has completed a single deal to date.

Its latest funding round, in April 2025, raised USD 1. 4 mn. Florey Biosciences specializes in engineered probiotics, with its flagship product being FLR-101, designed specifically for dietary management of gut microbiome disturbances caused by antibiotic use. FLR-101 is a medical food developed to work in conjunction with antibiotics, aiming to restore the balance of beneficial gut bacteria disrupted by such treatments.

The company utilizes a well-characterized food-grade yeast strain that is produced commercially in a scalable and cost-effective manner. Targeted primarily at healthcare providers and patients, Florey’s products are designed to enhance patient outcomes in the United States and other international markets, focusing on those suffering from antibiotic-associated disruptions to their gut health. Florey Biosciences' revenue model is structured around the sale of its medical food products, targeting healthcare institutions and professionals. Transactions occur through direct sales to healthcare providers and partnerships with distributors specializing in medical foods.

This B2B model ensures that Florey can efficiently reach end users—patients needing dietary management solutions for antibiotic-related gut disturbances. The company emphasizes a streamlined process where healthcare providers can order FLR-101 as part of their treatment protocols, enhancing the overall patient care strategy. Specific pricing plans for FLR-101 and other products are tailored for institutional clients, ensuring accessibility and compliance with healthcare standards. Florey Biosciences is focused on expanding its product line and market presence.

The company is currently developing new probiotic formulations aimed at broader dietary management solutions, with expected launches in late 2025. Additionally, Florey plans to enter European and Asian markets by 2026, leveraging its recent funding of USD 1. 4 mn raised in April 2025 to support these initiatives, enhance research and development, and establish distribution networks.